 MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202TJ202 in rr Multiple Myeloma in Mainland China PLANEGGMUNICH, GERMANY ACCESSWIRE April 27, 2020 MorphoSys FSE:MORPrime ... 